Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure

Table 1 Baseline characteristics of the study population

Characteristics			Group				Total		P value
			Metformin + DPP-4i		Metformin + SGLT2i		n	(%)
			n	(%)	n	(%)
Age in yr		≤ 60	12	37.5	19	59.4	31	49.2	0.178
		61-70	13	40.6	7	21.9	20	31.7
		> 70	7	21.9	6	18.8	13	19.0
Total			32	100.0	32	100.0	64	100.0
Sex		Males	18	56.3	18	56.3	36	56.3	0.999
		Females	14	43.8	14	43.8	28	43.8
Total			32	100.0	32	100.0	64	100.0
Body mass index in kg/m2		18.51-24.99	2	6.3			2	3.1	0.005a
		25.00-29.99	15	46.9	10	31.3	25	39.1
		30.00-34.99	14	43.8	11	34.4	25	39.1
		≥ 35.00	1	3.1	11	34.4	12	18.8
Total			32	100.0	32	100.0	64	100.0
Comorbidities	Arterial hypertension		28	87.5	22	68.8	50	78.1	0.066
	Hyperlipidemia		20	62.5	16	50.0	36	56.3	0.337
Drugs	ACEi/ARB		24	75.0	19	59.4	43	67.2	0.178
	Beta-blockers		8	25.0	8	25.0	16	25.0	0.999
	Calcium channel blockers		17	53.1	13	40.6	30	46.9	0.340
	Diuretics		15	46.9	12	37.5	27	42.2	0.470
	Moxonidine		8	25.0	5	15.6	13	20.3	0.378
	Statins		20	62.5	16	50.0	36	56.3	0.337
	Fibrates		1	3.1	2	6.3	3	4.7	0.567

^aP < 0.05.

ACEis: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-dependent glucose transporters inhibitors.